Ordovas J M
Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Clin Chem Lab Med. 2000 Oct;38(10):945-9. doi: 10.1515/CCLM.2000.139.
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that mediates the transfer of cholesteryl ester from high density lipoproteins (HDL) to triglyceride-rich lipoproteins in exchange for triglycerides. Several approaches are currently being used in research laboratories to measure its activity and/or mass. However, these assays are not standardized and it is not possible to compare data from different laboratories. Also, we lack enough information to assess the value of this variable as a coronary heart disease (CHD) predictor. Several genetic variants at CETP locus have been identified and they have been generally associated with increased HDL-cholesterol concentrations. However, there is no consensus about the association of this CETP-related increase in HDL-cholesterol and protection against CHD. Nevertheless, the most recent evidence from the common CETP-TaqI-B polymorphism shows that the lower CETP activity associated with the presence of this polymorphism decreases CHD risk in men. Based on this and previous evidence, there has been an interest in the development of CETP inhibitors as a tool to increase HOL-cholesterol, thus reducing CHD risk. However, it should be noted that the evidence about the cardioprotective role of these drugs is not yet available.
胆固醇酯转运蛋白（CETP）是一种血浆糖蛋白，它介导胆固醇酯从高密度脂蛋白（HDL）转移至富含甘油三酯的脂蛋白，以交换甘油三酯。目前研究实验室正在使用多种方法来测量其活性和/或质量。然而，这些检测方法尚未标准化，无法比较不同实验室的数据。此外，我们缺乏足够的信息来评估该变量作为冠心病（CHD）预测指标的价值。已在CETP基因座鉴定出几种基因变异，它们通常与HDL-胆固醇浓度升高有关。然而，关于CETP相关的HDL-胆固醇升高与预防CHD之间的关联尚无共识。尽管如此，来自常见的CETP-TaqI-B多态性的最新证据表明，与该多态性存在相关的较低CETP活性可降低男性患CHD的风险。基于此及先前的证据，人们对开发CETP抑制剂作为增加HDL-胆固醇从而降低CHD风险的工具产生了兴趣。然而，应该指出的是，关于这些药物心脏保护作用的证据尚不充分。
